Abstract: The present invention is enclosed in the area of panels for structural and decorative surfaces, in particular panels containing polymer-based materials, suitable for the coating of surfaces, for example, and containing such polymer-based materials in the respective layers. The present invention may relate to the integration of polymer granules, recycled or unrecycled, being particularly relevant when the granules are obtained from end-of-life polymer-based materials, for instance obtained from car tires into the core of compact laminate boards. It is therefore an object of the present invention a composite panel (100) for structural and decorative surfaces wherein it comprises a core panel, the core panel (10) comprising a mixture of granules of a polymeric material and a bonding element (1), the bonding element providing for the bonding of the granules of a polymeric material.

Abstract: A patient database system includes a patient database module and a patient database. The patient database may store longitudinal data for patients, and the patient database module may initially acquire a patient data value for a new patient, store the patient data value as part of the longitudinal data of the new patient, acquire further patient data values for the new patient, include the further patient data values as part of the longitudinal data of the new patient, retain the longitudinal data of the new patient for a time duration that extends through a plurality of medical processes having different time periods, compare the longitudinal data to a requirement of a clinical trial, and replenish the patient database with a patient data value of an additional patient. The patient database module may also perform a longitudinal data action on the longitudinal data of the new patient.

Abstract: A system for providing a patient engagement platform for clinical protocols may include modular components that interface with each other over a network. At least some of the modular components may perform a modular component operation. The modular components may include a patient database component to establish and update longitudinal data for patients including a first patient, where the longitudinal data for the first patient includes a plurality of patient data values. The modular components may include a journey management component to curate a journey of the first patient through a first clinical protocol, the journey including a plurality of touch points. The modular components may include a patient interaction component to receive a patient data value from the first patient and provide the patient data value to the patient database component, and to interact with the first patient according to at least one of the touch points.

Abstract: A method may include building a journey of a patient through a clinical protocol, where the journey includes a plurality of touch points, and engaging the patient with the plurality of touch points via communication channels. The touch points may include a prescreening touch point, an educational touch point, a transactional touch point, and an engagement touch point. The method may also include collecting further data values of the patient including medical information patient and behavioral information, storing the data values of the patient as longitudinal data, where the longitudinal data of the patient is stored for a time duration that extends after the first clinical protocol is completed by the patient, determining a preference of the patient for a specific one of the communication channels, and engaging the patient via the specific one of the communication channels for at least one of the touch points.

Abstract: A patient portal system may include a patient database module configured to interpret a patient profile value, a clinical database module configured to interpret a clinical study description, and a patient interface module configured to implement a patient clinical study interface in response to the patient profile value and the clinical study description.

Abstract: A patient portal system may include a patient database module to interpret a patient profile value and a clinical database module to interpret a clinical study description. The patient database module may also interpret patient clinical data in response to the patient profile value and the clinical study description, and include at least a portion of the patient clinical data as longitudinal data of a patient corresponding to the patient profile value. The system may also include a patient interface module to implement a patient engagement interface and to interpret a patient medical event value in response to patient interactions with the patient engagement interface. The patient database may also adjust the longitudinal data in response to the patient medical event value.

Abstract: There is provided a method to estimate a period characteristic, such as period length or a period location, of a physiological rhythm, such as a cardiac rhythm or a spontaneous breathing rhythm. The method comprises receiving the signal representing the physiological rhythm, estimating a first group of period characteristic estimations based on the signal, generating a prior probability for the period characteristic based on at least a subset of the first group of period characteristic estimations, and estimating a second group of period characteristic estimations based on the first group and the prior probability. By using this method, the accuracy of the signal is improved, especially when the signal is obtained from an accelerometer arranged on the chest of the subject.

Abstract: The present invention relates to the use of a combination of vitamins, more specifically to the combined use of biotin and thiamine, for the treatment of Huntington's disease. More specifically, the present invention explains that treatment with a combination of biotin and thiamine can improve the neurological, neuroimaging and spectroscopic symptoms associated with Huntington's disease.

Abstract: The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1-bromo-2-chloroethane in the presence of an organic base in a solvent to form ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof. Process step a) may be included in a process for preparing umeclidinium bromide that comprises further process steps: b) reacting ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof with lithium diisopropylamide in a solvent to form ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III); c) reacting ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III) with phenyl lithium in a solvent to form 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV); and d) reacting 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV) with ((2-bromoethoxy)methyl) benzene in a solvent to form 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I), umeclidinium bromide. A process comprising d) reacting 1-azabicyclo[2.2.

Abstract: The present application relates to a product made with food processing by-products/wastes in particular from the cocoa and chocolate industry, the coffee roasting industry, the wine and distillery industries, the beer industry, the olive oil industry and the fruits and vegetables industries, mixed with a binder, preferably a bio-based binder. The present application also relates to the method of manufacturing the product.

Abstract: The invention relates to a material formed by a polymer substrate and a hydrogel based on vinyl-lactams and ionic methacrylates. The invention also relates to a method for producing this material and to the use thereof for cell culture and cell monolayer engineering, for preparing 3D scaffolds and manufacturing thermosensitive mechanical actuators.

Abstract: The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1-bromo-2-chloroethane in the presence of an organic base in a solvent to form ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof. Process step a) may be included in a process for preparing umeclidinium bromide that comprises further process steps: b) reacting ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof with lithium diisopropylamide in a solvent to form ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III); c) reacting ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III) with phenyl lithium in a solvent to form 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV); and d) reacting 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV) with ((2-bromoethoxy)methyl) benzene in a solvent to form 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I), umeclidinium bromide. A process comprising d) reacting 1-azabicyclo[2.2.

Abstract: The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1-bromo-2-chloroethane in the presence of an organic base in a solvent to form ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof. Process step a) may be included in a process for preparing umeclidinium bromide that comprises further process steps: b) reacting ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof with lithium diisopropylamide in a solvent to form ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III); c) reacting ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III) with phenyl lithium in a solvent to form 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV); and d) reacting 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV) with ((2-bromoethoxy)methyl) benzene in a solvent to form 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I), umeclidinium bromide. A process comprising d) reacting 1-azabicyclo[2.2.

Abstract: The invention relates to a material formed by a polymer substrate and a hydrogel based on vinyl-lactams and ionic methacrylates. The invention also relates to a method for producing this material and to the use thereof for cell culture and cell monolayer engineering, for preparing 3D scaffolds and manufacturing thermosensitive mechanical actuators.

Abstract: The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1-bromo-2-chloroethane in the presence of an organic base in a solvent to form ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof. Process step a) may be included in a process for preparing umeclidinium bromide that comprises further process steps: b) reacting ethyl 1-(2-chloroethyl)piperidine-4-carboxylate (II) or a salt thereof with lithium diisopropylamide in a solvent to form ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III); c) reacting ethyl 1-azabicyclo[2.2.2]octane-4-carboxylate (III) with phenyl lithium in a solvent to form 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV); and d) reacting 1-azabicyclo[2.2.2]oct-4-yl(diphenyl)methanol (IV) with ((2-bromoethoxy)methyl) benzene in a solvent to form 4-[hydroxyl(diphenyl)methyl]-1-[2-(phenylmethyl)oxy]ethyl]-1-azoniabicyclo[2.2.2]octane bromide (I), umeclidinium bromide. A process comprising d) reacting 1-azabicyclo[2.2.

Abstract: A method of preventing or inhibiting infection by a parasite or virus in vivo comprising administering to a human in need thereof a parasite or virus mitogen in a sub-mitogenic amount sufficient to induce a protective immune response against the parasite or virus in the human.

Abstract: The invention relates to a DNA molecule from maize which codes for a protein with TGase activity and to a gene expression vector comprising said DNA molecule. The invention also relates to the use of the aforementioned DNA molecule or vector in order to produce transformed cells capable of expressing recombinant proteins with TGase activity and to introduce the sequence encoding for a protein with TGase activity into plant cells. In addition, the invention relates to the resulting transgenic plants and cells of microorganisms. Furthermore, the proteins with TGase activity expressed from the above-mentioned DNA sequences can be used, for example, in food manipulation, processing and transformation.